Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPureTech Regulatory News (PRTC)

Share Price Information for PureTech (PRTC)

Share Price is delayed by 15 minutes
Get Live Data
131.40    1.40 (1.08%)
Bid:
131.20
Ask:
132.60
Spread: 1.40 (1.067%)
Market Cap: £319.85m
PRTC Live PriceLast checked at - London Stock Exchange

Intraday PureTech Share Chart

BTG

14 Aug 2019 17:30

RNS Number : 0959J
FTSE Russell
14 August 2019
 

 

 

 

 

 

Further to the FTSE Russell notice released on 12 August 2019 in relation to BTG (UK): Constituent Deletion, please note the FTSE 250 replacement.

 

All other details remain unchanged. Please see updated notice below:

 

BTG (UK): Constituent Deletion - UpdateChanges in FTSE UK Index Series

14 August 2019

Subject to court sanctioning the scheme of arrangement in relation to the cash acquisition of BTG (UK, constituent) by Bravo Bidco Ltd (non constituent), please see details of affected indexes and effective dates below:

 

 

 

BTG (UK, 0100159) will be deleted from the FTSE 250 Index.

 

Puretech Health (UK, BY2Z0H7) will be added to the FTSE 250 Index and removed from the FTSE SmallCap Index.

 

All changes effective from 19 August 2019.

 

Full details of index changes are available on the FTSE Russell website.

 

 

 

 

 

For further information please contact FTSE Russell Client Services at info@ftserussell.com or call:

Australia

+1800 653 680

Hong Kong

+852 2164 3333

Japan

+81 3 4563 6346

London

+44 (0) 20 7866 1810

New York

+1866 551 0617

 

Alternatively please visit our website at www.ftserussell.com

Terms of Use | Copyright © 2019 FTSE Russell

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
FTSEZLFFKVFEBBL
Date   Source Headline
9th Apr 20204:41 pmRNSSecond Price Monitoring Extn
9th Apr 20204:35 pmRNSPrice Monitoring Extension
9th Apr 20207:00 amRNSFinal Results
1st Apr 20204:41 pmRNSSecond Price Monitoring Extn
1st Apr 20204:36 pmRNSPrice Monitoring Extension
27th Mar 20204:42 pmRNSSecond Price Monitoring Extn
27th Mar 20204:37 pmRNSPrice Monitoring Extension
24th Mar 202012:03 pmRNSPrice Monitoring Extension
20th Mar 202010:16 amRNSPrice Monitoring Extension
18th Mar 20204:42 pmRNSSecond Price Monitoring Extn
18th Mar 20204:37 pmRNSPrice Monitoring Extension
10th Mar 202010:00 amRNSGelesis: World’s Most Innovative Companies List
10th Mar 20207:00 amRNSNotice of Results
9th Mar 20204:41 pmRNSSecond Price Monitoring Extn
9th Mar 20204:36 pmRNSPrice Monitoring Extension
6th Mar 202012:02 pmRNSPrice Monitoring Extension
5th Mar 20204:40 pmRNSSecond Price Monitoring Extn
5th Mar 20204:35 pmRNSPrice Monitoring Extension
3rd Mar 20204:40 pmRNSSecond Price Monitoring Extn
3rd Mar 20204:36 pmRNSPrice Monitoring Extension
3rd Mar 202012:02 pmRNSPrice Monitoring Extension
3rd Mar 20207:00 amRNSClinical Trial Initiated Of Wholly-Owned Candidate
2nd Mar 20207:00 amRNSTotal Voting Rights
27th Feb 20204:41 pmRNSSecond Price Monitoring Extn
27th Feb 20204:36 pmRNSPrice Monitoring Extension
25th Feb 20207:00 amRNSAkili ADHD Study in The Lancet Digital Health
18th Feb 20207:00 amRNSPRTC to Present at Leerink Healthcare Conference
3rd Feb 20204:40 pmRNSSecond Price Monitoring Extn
3rd Feb 20204:35 pmRNSPrice Monitoring Extension
3rd Feb 20207:00 amRNSTotal Voting Rights
23rd Jan 20207:00 amRNSPureTech Receives $200M from KRTX Shares
15th Jan 20201:04 pmRNSAkili's New ADHD Trial Met Primary Endpoint
13th Jan 202012:07 pmRNSSecond Price Monitoring Extn
13th Jan 202012:02 pmRNSPrice Monitoring Extension
2nd Jan 20207:00 amRNSTotal Voting Rights
19th Dec 20197:00 amRNSFollica Positive Androgenetic Alopecia Study
17th Dec 201912:00 pmRNSGelesis Partners with US Telehealth Provider
12th Dec 20191:04 pmRNSAkili Meets Primary Endpoint in MDD Clinical Trial
10th Dec 201912:02 pmRNSPrice Monitoring Extension
10th Dec 20197:00 amRNSVedanta & BMS Begin Immuno-Oncology Clinical Study
9th Dec 20197:00 amRNSGelesis Attracts $84M in New Capital for Launch
5th Dec 20197:00 amRNSVedanta MultiDrug Resistance Program Granted $5.8M
2nd Dec 20197:00 amRNSTotal Voting Rights
25th Nov 201912:02 pmRNSPrice Monitoring Extension
21st Nov 20197:00 amRNSKaruna Prices $250M Follow-On Offering
18th Nov 201911:03 amRNSKaruna Successful Ph2 Schizophrenia Study Readout
15th Nov 201912:51 pmRNSresTORbio Update on Phase 3 Trial
13th Nov 20197:00 amRNSPureTech to Present at Jefferies London Conference
5th Nov 20191:00 pmRNSPRTC Presents Novel Oncology Program Data at SITC
5th Nov 201911:00 amRNSGelesis Shares New Plenity Safety & Efficacy Data

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.